Chromosome 9p21.3 Coordinates Cell Intrinsic and Extrinsic Tumor Suppression
S. Lowe, F. M. Barriga, K. M. Tsanov, Y. J. Ho, N. Sohail, A. Zhang, T. Baslan, A. N. Wuest, I. Del Priore, B. Meskauskaite, G. Livshits, D. Alonso-Curbelo, J. Simon, A. Chaves-Perez, D. Bar-Sagi, C. A. Iacobuzio-Donahue, F. Notta, R. Chaligne, R. Sharma, D. Pe'er
Abstract
Somatic chromosomal deletions are prevalent in cancer, yet their functional contributions remain ill-defined. Among the most prominent of these events are deletions of chromosome 9p21.3, which disable a cell intrinsic barrier to tumorigenesis by eliminating the CDKN2A/B tumor suppressor genes. However, half of 9p21.3 deletions encompass a cluster of 16 type I interferons (IFNs) whose co-deletions have not been functionally characterized. To dissect how 9p21.3 and other genomic deletions impact cancer, we developed MACHETE (Molecular Alteration of Chromosomes with Engineered Tandem Elements), a genome engineering strategy that enables flexible modeling of megabase-sized deletions. Generation of 9p21.3-syntenic deletions in a mouse model of pancreatic cancer revealed that concomitant loss of Cdkn2a/b and the IFN cluster led to immune evasion and metastasis compared to Cdkn2a/b-only deletions. Mechanistically, IFN co-deletion disrupted type I IFN signaling, altered antigen-presenting cells, and facilitated escape from CD8+ T cell surveillance in a cell extrinsic manner requiring loss of interferon epsilon (Ifne). Our results establish co-deletions of the IFN cluster as a pervasive route to tumor immune evasion and metastasis, revealing how deletions can disable physically linked cell intrinsic and extrinsic tumor suppression. Our study establishes a framework to dissect the functions of genomic deletions in cancer and beyond.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Prevailing homozygous deletion of interferon and defensin genes in human cancers
Zhenqing Ye, Haidong Dong, … Liguo Wang·bioRxiv·Jan 19, 2017
- The PTPN1 and PTPN2 phosphatases are Cooperative Regulators of Cancer Cell Immune Evasion
Alexandre Poirier, Erika Walback, … Michel L. Tremblay·bioRxiv·Jul 2, 2025
- PTPN2 deletion in T cells promotes anti-tumour immunity and CAR T cell efficacy in solid tumours
F. Wiede, K.-H. Lu, … T. Tiganis·bioRxiv·Sep 5, 2019
- On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions
Linda Julian, Lisa Crozier, … Jason M. Sheltzer·bioRxiv·Aug 3, 2025
- Chromosome 3p deletion leads to extensive genomic alterations in diverse cancers and confers synthetic lethality in uveal melanoma
Mitchell C. Cutler, Porter B Howland, … Jun S. Song·CancersPeer-reviewed·Feb 19, 2026
- Head-to-head comparison of CCN4, DNMT3A, PTPN11, and SPARC as suppressors of anti-tumor immunity
A. C. Pirkey, W. Deng, … D. J. Klinke·bioRxiv·Apr 1, 2022